{"disease":{"id":"treatment-refractory-type-2-diabetes-mellitus","name":"Treatment Refractory Type 2 Diabetes Mellitus","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"glimepiride","indication_name":"Treatment Refractory Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amaryl","generic_name":"GLIMEPIRIDE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea [EPC]","quality_score":62,"revenue":null,"mechanism":"Amaryl works by binding to the sulfonylurea receptor 1 (SUR1) and Kir6.2 subunit of the ATP-sensitive potassium channel, closing the channel and depolarizing the pancreatic beta cell membrane, leading to insulin release."},{"drug_id":"rosiglitazone","indication_name":"Treatment Refractory Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avandia","generic_name":"ROSIGLITAZONE","company_name":"Woodward","drug_phase":"marketed","molecular_target":"CDGSH iron-sulfur domain-containing protein 1","drug_class":"Peroxisome Proliferator Receptor gamma Agonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"metformin","indication_name":"Treatment Refractory Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glucophage","generic_name":"metformin","company_name":"Generic (originally Merck Serono/Lipha)","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Activates AMP-activated protein kinase (AMPK) to reduce hepatic glucose production and improve insulin sensitivity without causing hypoglycemia."},{"drug_id":"glucophage","indication_name":"Treatment Refractory Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Glucophage","company_name":"Dr. Reddy's Laboratories Limited","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"metformin","guideline_body":"FDA label","recommendation":"ZITUVIMET can be used in patients with treatment-refractory type 2 diabetes mellitus.","line_of_therapy":"2L+","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}